Pan Dong-liang, Li Han-zhong, Ji Zhi-gang, Zeng Zheng-pei
Department of Urology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
Zhonghua Yi Xue Za Zhi. 2005 Jun 1;85(20):1403-5.
To compare the effects of doxazosin mosylate and phenoxybenzamine in preoperative volume expansion of pheochromocytoma.
Phenoxybenzamine 30-240 mg/d was given orally to 38 patients of pheochromcytoma for 3 weeks. After the blood pressure was restored to the primary level before taking phenoxybenzamine, doxazosin mosylate 2-8 mg/d was given orally for three weeks. If the maximum dose of doxazosin mosylate (16 mg/d) still failed to achieve efficient blood volume expansion then phenoxybenzamine was added till completely efficient blood volume expansion was achieved. The effect in volume expansion and side effects were observed with the criteria including decrease of blood pressure to less than 120/80 mm Hg and restoration of the microcirculation imaging to normal.
All the patients got complete volume expansion after taking phenoxybenzamine with tachycardia occurring in 23 of them and postural hypotension in 13 patients. In the 25 cases mainly with increase of norepinephrine before medical treatment doxazosin mosylate was completely effective in 18 cases with their blood pressure < 180/140 mm Hg; and was partially effective in the other 7 cases with their blood pressure > 180/140 mm Hg of which 2 suffered from postural hypotension. Doxazosin mosylate was partially effective in the other 13 cases mainly with increase of both norepinephrine and epinephrine. The total efficiency rate of these two medicines was not significantly different (chi(2) = 18.05, P > 0.05). The side-effect rate of doxazosin mosylate was significantly lower than that of phenoxybenzamine (chi(2) = 324, P < 0.01).
Doxazosin mosylate has a lower complete volume expansion rate and side-effect rate as well for patients of pheochromocytoma. Pheochromocytomas with mild or moderate level of blood pressure are indicative of the use of doxazosin mosylate.
比较甲磺酸多沙唑嗪与酚苄明在嗜铬细胞瘤术前扩容中的效果。
38例嗜铬细胞瘤患者口服酚苄明30 - 240mg/d,共3周。血压恢复至服用酚苄明前的基础水平后,口服甲磺酸多沙唑嗪2 - 8mg/d,共3周。若甲磺酸多沙唑嗪最大剂量(16mg/d)仍未能有效扩容,则加用酚苄明直至达到完全有效扩容。观察扩容效果及副作用,标准包括血压降至120/80mmHg以下以及微循环成像恢复正常。
所有患者服用酚苄明后均实现完全扩容,其中23例出现心动过速,13例出现体位性低血压。在25例治疗前主要以去甲肾上腺素升高为主的患者中,甲磺酸多沙唑嗪18例完全有效,血压<180/140mmHg;另7例部分有效,血压>180/140mmHg,其中2例出现体位性低血压。甲磺酸多沙唑嗪在另13例主要以去甲肾上腺素和肾上腺素均升高为主的患者中部分有效。两种药物的总有效率差异无统计学意义(χ² = 18.05,P>0.05)。甲磺酸多沙唑嗪的副作用发生率显著低于酚苄明(χ² = 324,P<0.01)。
对于嗜铬细胞瘤患者,甲磺酸多沙唑嗪的完全扩容率和副作用发生率均较低。血压轻度或中度升高的嗜铬细胞瘤患者适合使用甲磺酸多沙唑嗪。